Back to Browse Journals » Biologics: Targets and Therapy » Volume 2 » Issue 4

The insulin-like growth factor system and its receptors: A potential novel anticancer target

Authors Colin R. Lindsay, T R Jeffry Evans

Published 5 December 2008 Volume 2008:2(4) Pages 855—864

DOI http://dx.doi.org/10.2147/BTT.S3841

Review by Single-blind

Peer reviewer comments 3

Colin R. Lindsay1, T R Jeffry Evans1,2

1Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; 2University of Glasgow, CR-UK Beatson Laboratories, Garscube Estate, Glasgow, United Kingdom

Abstract: The current generation of novel anticancer therapies that are in preclinical and clinical development are based on exploiting our increasing understanding of the molecular and cellular basis of cancer development and progression. Accelerated rates of cell division and proliferation have been postulated to predispose to the development of malignant disease. The insulin-like growth factor (IGF) signaling system has an important physiological role in regulating cellular proliferation and apoptosis. This function has led to considerable interest in its relevance to neoplasia over the last decade. In this review, we give an overview of the IGF system physiology, discuss the epidemiological significance of IGF signaling and neoplasia, and review the preclinical and clinical studies in targeting IGF receptors as cancer therapies.

Keywords: insulin, growth factor, IGF-1, clinical trials

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Cetuximab: its unique place in head and neck cancer treatment

Specenier P, Vermorken JB

Biologics: Targets and Therapy 2013, 7:77-90

Published Date: 15 April 2013

Lebrikizumab in the personalized management of asthma

Thomson NC, Patel M, Smith AD

Biologics: Targets and Therapy 2012, 6:329-335

Published Date: 14 September 2012

Natural killer cells: role in local tumor growth and metastasis

Langers I, Renoux VM, Thiry M, Delvenne P, Jacobs N

Biologics: Targets and Therapy 2012, 6:73-82

Published Date: 5 April 2012

An update on belimumab for the treatment of lupus

Aikaterini Thanou-Stavraki, Amr H Sawalha,

Biologics: Targets and Therapy 2011, 5:33-43

Published Date: 14 February 2011

Adalimumab for the treatment of Crohn’s disease

Andrea Cassinotti, Sandro Ardizzone, Gabriele Bianchi Porro

Biologics: Targets and Therapy 2008, 2:763-777

Published Date: 5 December 2008

Sorafenib for the treatment of unresectable hepatocellular carcinoma

Junji Furuse

Biologics: Targets and Therapy 2008, 2:779-788

Published Date: 5 December 2008

Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside

Ana Villegas, Fernando A Gonzalez, Leopoldo Llorente, Santiago Redondo

Biologics: Targets and Therapy 2008, 2:397-407

Published Date: 12 September 2008

Novel targets for immunotherapy in glomerulonephritis

Mary H Foster

Biologics: Targets and Therapy 2008, 2:531-545

Published Date: 12 September 2008

New treatment options in the management of IBD – focus on colony stimulating factors

Josué Barahona-Garrido, Jesús K Yamamoto-Furusho

Biologics: Targets and Therapy 2008, 2:501-504

Published Date: 12 September 2008